关注
Giampaolo Bianchini
Giampaolo Bianchini
未知所在单位机构
在 hsr.it 的电子邮件经过验证
标题
引用次数
引用次数
年份
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
G Bianchini, JM Balko, IA Mayer, ME Sanders, L Gianni
Nature reviews Clinical oncology 13 (11), 674-690, 2016
24702016
Treatment landscape of triple-negative breast cancer—expanded options, evolving needs
G Bianchini, C De Angelis, L Licata, L Gianni
Nature reviews Clinical oncology 19 (2), 91-113, 2022
6062022
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label …
SA Hurvitz, R Hegg, WP Chung, SA Im, W Jacot, V Ganju, JWY Chiu, B Xu, ...
The Lancet 401 (10371), 105-117, 2023
2962023
The immune system and response to HER2-targeted treatment in breast cancer
G Bianchini, L Gianni
The Lancet Oncology 15 (2), e58-e68, 2014
2932014
Immunological differences between primary and metastatic breast cancer
B Szekely, V Bossuyt, X Li, VB Wali, GA Patwardhan, C Frederick, A Silber, ...
Annals of Oncology 29 (11), 2232-2239, 2018
2862018
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP …
L Gianni, CS Huang, D Egle, B Bermejo, C Zamagni, M Thill, A Anton, ...
Annals of Oncology 33 (5), 534-543, 2022
2752022
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer
T Iwamoto, G Bianchini, D Booser, Y Qi, C Coutant, C Ya-Hui Shiang, ...
Journal of the National Cancer Institute 103 (3), 264-272, 2011
2562011
based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study
A Prat, G Bianchini, M Thomas, A Belousov, MCU Cheang, A Koehler, ...
Clinical Cancer Research 20 (2), 511-521, 2014
2482014
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor–positive and–negative cancers
G Bianchini, Y Qi, RH Alvarez, T Iwamoto, C Coutant, NK Ibrahim, ...
Journal of Clinical Oncology 28 (28), 4316-4323, 2010
2232010
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ...
Annals of oncology 33 (12), 1250-1268, 2022
1982022
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation
K Liang, FJ Esteva, C Albarracin, K Stemke-Hale, Y Lu, G Bianchini, ...
Cancer cell 18 (5), 423-435, 2010
1722010
New strategies in breast cancer: immunotherapy
L Pusztai, T Karn, A Safonov, MM Abu-Khalaf, G Bianchini
Clinical Cancer Research 22 (9), 2105-2110, 2016
1532016
DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes
L Santarpia, T Iwamoto, A Di Leo, N Hayashi, G Bottai, M Stampfer, ...
The oncologist 18 (10), 1063-1073, 2013
1532013
Association between genomic metrics and immune infiltration in triple-negative breast cancer
T Karn, T Jiang, C Hatzis, N Sänger, A El-Balat, A Rody, U Holtrich, ...
JAMA oncology 3 (12), 1707-1711, 2017
1512017
Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer—the evaluating treatment with …
L Gianni, M Mansutti, A Anton, L Calvo, G Bisagni, B Bermejo, ...
JAMA oncology 4 (3), 302-308, 2018
1482018
Comparison of tumor‐infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients
R Ogiya, N Niikura, N Kumaki, G Bianchini, S Kitano, T Iwamoto, ...
Cancer science 107 (12), 1730-1735, 2016
1412016
Immune gene expression is associated with genomic aberrations in breast cancer
A Safonov, T Jiang, G Bianchini, B Győrffy, T Karn, C Hatzis, L Pusztai
Cancer research 77 (12), 3317-3324, 2017
1352017
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial
G Bianchini, L Pusztai, T Pienkowski, YH Im, GV Bianchi, LM Tseng, ...
Annals of Oncology 26 (12), 2429-2436, 2015
1352015
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre …
F André, YH Park, SB Kim, T Takano, SA Im, G Borges, JP Lima, S Aksoy, ...
The Lancet 401 (10390), 1773-1785, 2023
1222023
Synthetic lethal approaches exploiting DNA damage in aggressive myeloma
F Cottini, T Hideshima, R Suzuki, YT Tai, G Bianchini, PG Richardson, ...
Cancer discovery 5 (9), 972-987, 2015
1182015
系统目前无法执行此操作,请稍后再试。
文章 1–20